Selenium

證據等級: L5

預測適應症: 1 個

Selenium: From Nutritional Supplementation to Sclerosing Cholangitis

One-Sentence Summary

Selenium is an essential trace element recognised for its role in antioxidant enzyme systems, and is used clinically as a nutritional supplement rather than for a formally approved therapeutic indication. The TxGNN model predicts it may have therapeutic potential in Sclerosing Cholangitis, with no registered clinical trials and 5 observational or review publications currently supporting this direction. The overall evidence base remains preclinical and hypothesis-generating.

Quick Overview

Item	Content
Original Indication	Nutritional supplementation (essential trace element; no formal approved therapeutic indication on record)
Predicted New Indication	Sclerosing Cholangitis
TxGNN Prediction Score	99.04%
Evidence Level	L4
UK Market Status	Not authorised in the UK
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Selenium is an essential trace element that is biologically incorporated as selenocysteine into key antioxidant enzymes, including glutathione peroxidase (GPx) and thioredoxin reductase. These enzymes are central to the cellular defence against oxidative damage, and selenium has been investigated in a range of inflammatory and fibrotic conditions for its potential to attenuate oxidative stress pathways.

Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic liver disease characterised by biliary inflammation and fibrosis, driven in part by oxidative stress, TGF-β-mediated fibrogenesis, and dysregulation of the gut–biliary axis. Published observational data (PMID 9053974) have documented abnormal hepatic selenium retention in PSC patients, suggesting that selenium metabolism may be perturbed in this disease. Whether this reflects a causative factor or a secondary consequence of impaired biliary function remains unresolved.

The TxGNN model’s high prediction score (99.04%) most likely reflects a knowledge graph pathway linking GPx → oxidative stress → biliary fibrosis. Whilst mechanistically plausible, this remains a computational inference. No interventional studies have examined whether selenium supplementation can meaningfully reduce biliary inflammation or slow fibrosis progression in PSC. This prediction should therefore be regarded as hypothesis-generating rather than practice-informing at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered for Selenium in sclerosing cholangitis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9053974	1995	Cross-sectional / Observational	Scandinavian Journal of Gastroenterology	Trace element metabolism studied in 32 PSC patients; hepatic copper and selenium retention identified, suggesting abnormal selenium metabolism in PSC
39601354	2025	Dietary Survey / Cross-sectional	Liver International	Evaluated dietary intake in PSC patients vs Nordic Nutrition Recommendations 2023; poor fat-soluble vitamin intake and suboptimal overall dietary quality documented
29148959	2017	Clinical Study / Nutrition	JPEN: Journal of Parenteral and Enteral Nutrition	Case report of parenteral nutrition management in overlapping PSC and ulcerative colitis; discusses oxidative stress and antioxidant deficiency as contributors to cholestatic disease pathogenesis
17109383	2006	Animal Model / Proteomics	Proteomics	Hepatic proteome changes characterised in murine models of toxic-induced fibrogenesis and sclerosing cholangitis; mechanistic basis of hepatic protein expression changes discussed
18941372	2008	Review / Chemoprevention	European Journal of Cancer Prevention	Review of chemopreventive agents in colorectal cancer, including selenium; indirect relevance to PSC-associated colorectal cancer risk only

UK Market Information

Selenium (DrugBank ID: DB11135) currently holds no MHRA marketing authorisation. There are no licensed medicinal products on the UK market for this compound as a standalone therapeutic agent.

Note: Selenium-containing formulations are available as unlicensed dietary supplements and may appear as a micronutrient component within licensed parenteral nutrition solutions. However, no product holds a UK marketing authorisation for selenium as a named therapeutic indication.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Additional note for prescribers: Selenium has a narrow therapeutic window. Chronic intake above approximately 400 µg/day may result in selenosis (hair loss, nail brittleness, gastrointestinal disturbance, peripheral neuropathy). Any interventional use outside of nutritional support should be subject to formal dose-finding evaluation and toxicity monitoring.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction is mechanistically plausible given selenium’s antioxidant properties and documented perturbation of selenium metabolism in PSC, but the evidence base is entirely observational and preclinical (L4), with no registered interventional trials and no MHRA marketing authorisation for any therapeutic indication.

To proceed, the following is needed:

Systematic review or meta-analysis of selenium status and supplementation outcomes in PSC and related cholestatic liver diseases
Proof-of-concept interventional study (e.g., pilot RCT assessing selenium supplementation in PSC patients with confirmed selenium deficiency)
Detailed mechanism of action data (MOA) confirming GPx-mediated antifibrotic activity specifically within biliary epithelium
Safety and dose-ranging data at therapeutic (as opposed to nutritional supplementation) dosing levels, given selenium’s narrow therapeutic index
Early regulatory dialogue with MHRA to establish a viable development pathway for an unlicensed indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.